Fig. 5. An Aβ₄₂ neutralising antibody prevents further impairment of cardiac relaxation in established obesity.

a schematic of experiment where mice fed either chow or a high-fat diet (HFD) for 4 months and were administered a control antibody or an Aβ₄₂ neutralising antibody (3D6) once weekly in the final month of the diet period. Analysis of cardiac function and morphology was performed at the beginning and of the experiment (baseline), prior to the treatment period (pre-treatment) and at the end of the treatment period (post-treatment). b body weight over time in mice fed regular chow or HFD and administered control or 3D6 antibodies (n = 12/group). c deceleration time in mice at Baseline, pre-treatment and post-treatment after 4 months of chow or high fat feeding and antibody administration (mixed-effects model (time P < 0.0001, F(2,93) = 31.56; treatment P = 0.0151, F(2,93) = 4.390) and Sidak’s multiple comparisons test P.adjusted; n = 12/group). d cardiac glucose clearance (n = 8, 9 and 9/group respectively), and; e cardiac triglycerides (TG; One-way ANOVA, P = 0.0082, F(2,31) = 5.624; n = 12, 12 and 10/group respectively) in mice fed regular chow and administered control antibody, or mice fed a high fat diet (HFD) and administered control or 3D6 antibodies. All data are mean ± SEM. Statistical tests are two-tailed. Source data are provided in the Source Data file. Elements of a are created with BioRender.com.